<DOC>
	<DOC>NCT01997229</DOC>
	<brief_summary>The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.</brief_summary>
	<brief_title>Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Key Male or female patients ≥18 years old Diagnosis of MG made by the following tests: 1. Positive serologic test for antiAChR Abs as confirmed at screening, and 2. One of the following: 1. History of abnormal neuromuscular transmission test demonstrated by singlefiber electromyography (SFEMG) or repetitive nerve stimulation, or 2. History of positive anticholinesterase test, e.g. edrophonium chloride test, or 3. Subject has demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician. MGFA Clinical Classification Class II to IV at screening. MGADL total score must be ≥6 at screening and Randomization (Day 1). Subjects who have: 1. Failed treatment with at least two immunosuppressive agents. Or, 2. Failed treatment with at least one immunosuppressive agent and require chronic plasma exchange or IVIg Key History of thymoma or other neoplasms of the thymus History of thymectomy within 12 months prior to screening MGFA Class I or MG crisis at screening (MGFA Class V) Use of rituximab within 6 months prior to screening Use of IVIg or PE within 4 weeks prior to Randomization (Day 1)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>